|
1
|
Lenz G and Staudt LM: Aggressive
lymphomas. N Engl J Med. 362:1417–1429. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Klein U and Dalla-Favera R: Germinal
centres: Role in B-cell physiology and malignancy. Nat Rev Immunol.
8:22–33. 2008. View
Article : Google Scholar
|
|
3
|
Andreadis C, Gimotty PA, Wahl P, Hammond
R, Houldsworth J, Schuster SJ and Rebbeck TR: Members of the
glutathione and ABC-transporter families are associated with
clinical outcome in patients with diffuse large B-cell lymphoma.
Blood. 109:3409–3416. 2007. View Article : Google Scholar
|
|
4
|
Sehn LH and Gascoyne RD: Diffuse large
B-cell lymphoma: Optimizing outcome in the context of clinical and
biologic heterogeneity. Blood. 125:22–32. 2015. View Article : Google Scholar
|
|
5
|
Maurer MJ, Ghesquières H, Jais JP, Witzig
TE, Haioun C, Thompson CA, Delarue R, Micallef IN, Peyrade F, Macon
WR, et al: Event-free survival at 24 months is a robust end point
for disease-related outcome in diffuse large B-cell lymphoma
treated with immunochemotherapy. J Clin Oncol. 32:1066–1073. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Küppers R: B cells under influence:
Transformation of B cells by Epstein-Barr virus. Nat Rev Immunol.
3:801–812. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ok CY, Papathomas TG, Medeiros LJ and
Young KH: EBV-positive diffuse large B-cell lymphoma of the
elderly. Blood. 122:328–340. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Montes-Moreno S, Odqvist L, Diaz-Perez JA,
Lopez AB, de Villambrosía SG, Mazorra F, Castillo ME, Lopez M,
Pajares R, García JF, et al: EBV-positive diffuse large B-cell
lymphoma of the elderly is an aggressive post-germinal center
B-cell neoplasm characterized by prominent nuclear factor-κB
activation. Mod Pathol. 25:968–982. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Roberts ML and Cooper NR: Activation of a
ras-MAPK-dependent pathway by Epstein-Barr virus latent membrane
protein 1 is essential for cellular transformation. Virology.
240:93–99. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dawson CW, Tramountanis G, Eliopoulos AG
and Young LS: Epstein-Barr virus latent membrane protein 1 (LMP1)
activates the phosphatidylinositol 3-kinase/Akt pathway to promote
cell survival and induce actin filament remodeling. J Biol Chem.
278:3694–3704. 2003. View Article : Google Scholar
|
|
11
|
Kondo S, Wakisaka N, Muramatsu M, Zen Y,
Endo K, Murono S, Sugimoto H, Yamaoka S, Pagano JS and Yoshizaki T:
Epstein-Barr virus latent membrane protein 1 induces cancer
stem/progenitor-like cells in nasopharyngeal epithelial cell lines.
J Virol. 85:11255–11264. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mo W and Zhang JT: Human ABCG2: Structure,
function, and its role in multidrug resistance. Int J Biochem Mol
Biol. 3:1–27. 2012.PubMed/NCBI
|
|
13
|
Ambudkar SV, Dey S, Hrycyna CA,
Ramachandra M, Pastan I and Gottesman MM: Biochemical, cellular,
and pharmacological aspects of the multidrug transporter. Annu Rev
Pharmacol Toxicol. 39:361–398. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ueda K: ABC proteins protect the human
body and maintain optimal health. Biosci Biotechnol Biochem.
75:401–409. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ohsawa M, Ikura Y, Fukushima H, Shirai N,
Sugama Y, Suekane T, Hirayama M, Hino M and Ueda M:
Immunohistochemical expression of multidrug resistance proteins as
a predictor of poor response to chemotherapy and prognosis in
patients with nodal diffuse large B-cell lymphoma. Oncology.
68:422–431. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kurosaki T, Takata M, Yamanashi Y, Inazu
T, Taniguchi T, Yamamoto T and Yamamura H: Syk activation by the
Src-family tyrosine kinase in the B cell receptor signaling. J Exp
Med. 179:1725–1729. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Beitz LO, Fruman DA, Kurosaki T, Cantley
LC and Scharenberg AM: SYK is upstream of phosphoinositide 3-kinase
in B cell receptor signaling. J Biol Chem. 274:32662–32666. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fujimoto M, Fujimoto Y, Poe JC, Jansen PJ,
Lowell CA, DeFranco AL and Tedder TF: CD19 regulates Src family
protein tyrosine kinase activation in B lymphocytes through
processive amplification. Immunity. 13:47–57. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Herman SE, Gordon AL, Wagner AJ, Heerema
NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ,
et al: Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows
promising preclinical activity in chronic lymphocytic leukemia by
antagonizing intrinsic and extrinsic cellular survival signals.
Blood. 116:2078–2088. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ringshausen I, Schneller F, Bogner C, Hipp
S, Duyster J, Peschel C and Decker T: Constitutively activated
phosphati-dylinositol-3 kinase (PI-3K) is involved in the defect of
apoptosis in B-CLL: Association with protein kinase Cdelta. Blood.
100:3741–3748. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hofmann C, Stühmer T, Schmiedl N, Wetzker
R, Mottok A, Rosenwald A, Langer C, Zovko J, Chatterjee M, Einsele
H, et al: PI3K-dependent multiple myeloma cell survival is mediated
by the PIK3CA isoform. Br J Haematol. 166:529–539. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ikeda H, Hideshima T, Fulciniti M, Perrone
G, Miura N, Yasui H, Okawa Y, Kiziltepe T, Santo L, Vallet S, et
al: PI3K/p110{delta} is a novel therapeutic target in multiple
myeloma. Blood. 116:1460–1468. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fruman DA and Cantley LC: Idelalisib: a
PI3Kδ inhibitor for B-cell cancers. N Engl J Med. 370:1061–1062.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Witzig TE, Reeder CB, LaPlant BR, Gupta M,
Johnston PB, Micallef IN, Porrata LF, Ansell SM, Colgan JP,
Jacobsen ED, et al: A phase II trial of the oral mTOR inhibitor
everolimus in relapsed aggressive lymphoma. Leukemia. 25:341–347.
2011. View Article : Google Scholar :
|
|
25
|
Zou P, Kawada J, Pesnicak L and Cohen JI:
Bortezomib induces apoptosis of Epstein-Barr virus
(EBV)-transformed B cells and prolongs survival of mice inoculated
with EBV-transformed B cells. J Virol. 81:10029–10036. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen L, Monti S, Juszczynski P, Daley J,
Chen W, Witzig TE, Habermann TM, Kutok JL and Shipp MA:
SYK-dependent tonic B-cell receptor signaling is a rational
treatment target in diffuse large B-cell lymphoma. Blood.
111:2230–2237. 2008. View Article : Google Scholar
|
|
27
|
Chen L, Monti S, Juszczynski P, Ouyang J,
Chapuy B, Neuberg D, Doench JG, Bogusz AM, Habermann TM, Dogan A,
et al: SYK inhibition modulates distinct PI3K/AKT-dependent
survival pathways and cholesterol biosynthesis in diffuse large B
cell lymphomas. Cancer Cell. 23:826–838. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yang C, Atkinson SP, Vilella F, Lloret M,
Armstrong L, Mann DA and Lako M: Opposing putative roles for
canonical and noncanonical NF-κB signaling on the survival,
proliferation, and differentiation potential of human embryonic
stem cells. Stem Cells. 28:1970–1980. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ancín I, Sarrá J, Peris J, Romagosa V,
Domingo-Claros A and Grañena A: Demonstration of Epstein-Barr virus
in a case of multiple myeloma after renal transplantation.
Haematologica. 85:773–774. 2000.PubMed/NCBI
|
|
30
|
Tcheng WY, Said J, Hall T, Al-Akash S,
Malogolowkin M and Feig SA: Post-transplant multiple myeloma in a
pediatric renal transplant patient. Pediatr Blood Cancer.
47:218–223. 2006. View Article : Google Scholar
|
|
31
|
Voelkerding KV, Sandhaus LM, Kim HC,
Wilson J, Chittenden T, Levine AJ and Raska K Jr: Plasma cell
malignancy in the acquired immune deficiency syndrome. Association
with Epstein-Barr virus. Am J Clin Pathol. 92:222–228. 1989.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Deane JA and Fruman DA: Phosphoinositide
3-kinase: Diverse roles in immune cell activation. Annu Rev
Immunol. 22:563–598. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chantry D, Vojtek A, Kashishian A,
Holtzman DA, Wood C, Gray PW, Cooper JA and Hoekstra MF: p110delta,
a novel phosphatidylinositol 3-kinase catalytic subunit that
associates with p85 and is expressed predominantly in leukocytes. J
Biol Chem. 272:19236–19241. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Vanhaesebroeck B, Welham MJ, Kotani K,
Stein R, Warne PH, Zvelebil MJ, Higashi K, Volinia S, Downward J
and Waterfield MD: P110delta, a novel phosphoinositide 3-kinase in
leukocytes. Proc Natl Acad Sci USA. 94:4330–4335. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ismail SI, Mahmoud IS, Msallam MM and
Sughayer MA: Hotspot mutations of PIK3CA and AKT1 genes are absent
in multiple myeloma. Leuk Res. 34:824–826. 2010. View Article : Google Scholar
|
|
36
|
Leupin N, Cenni B, Novak U, Hügli B,
Graber HU, Tobler A and Fey MF: Disparate expression of the PTEN
gene: A novel finding in B-cell chronic lymphocytic leukaemia
(B-CLL). Br J Haematol. 121:97–100. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Georgakis GV, Li Y, Rassidakis GZ,
Medeiros LJ, Mills GB and Younes A: Inhibition of the
phosphatidylinositol-3 kinase/Akt promotes G1 cell cycle arrest and
apoptosis in Hodgkin lymphoma. Br J Haematol. 132:503–511.
2006.PubMed/NCBI
|
|
38
|
Shostak K and Chariot A: NF-κB, stem cells
and breast cancer: The links get stronger. Breast Cancer Res.
13:2142011. View Article : Google Scholar
|
|
39
|
Adam P, Bonzheim I, Fend F and
Quintanilla-Martínez L: Epstein-Barr virus-positive diffuse large
B-cell lymphomas of the elderly. Adv Anat Pathol. 18:349–355. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hoeller S, Tzankov A, Pileri SA, Went P
and Dirnhofer S: Epstein-Barr virus-positive diffuse large B-cell
lymphoma in elderly patients is rare in Western populations. Hum
Pathol. 41:352–357. 2010. View Article : Google Scholar
|
|
41
|
Park S, Lee J, Ko YH, Han A, Jun HJ, Lee
SC, Hwang IG, Park YH, Ahn JS, Jung CW, et al: The impact of
Epstein-Barr virus status on clinical outcome in diffuse large
B-cell lymphoma. Blood. 110:972–978. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Sato A, Nakamura N, Kojima M, Ohmachi K,
Carreras J, Kikuti YY, Numata H, Ohgiya D, Tazume K, Amaki J, et
al: Clinical outcome of Epstein-Barr virus-positive diffuse large
B-cell lymphoma of the elderly in the rituximab era. Cancer Sci.
105:1170–1175. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Hong JY, Yoon DH, Suh C, Huh J, Do IG,
Sohn I, Jo J, Jung SH, Hong ME, Yoon H, et al: EBV-positive diffuse
large B-cell lymphoma in young adults: Is this a distinct disease
entity? Ann Oncol. 26:548–555. 2015. View Article : Google Scholar
|
|
44
|
Richardson PG, Sonneveld P, Schuster MW,
Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D,
Lonial S, Goldschmidt H, et al Assessment of Proteasome Inhibition
for Extending Remissions (APEX) Investigators: Bortezomib or
high-dose dexamethasone for relapsed multiple myeloma. N Engl J
Med. 352:2487–2498. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
San Miguel JF, Schlag R, Khuageva NK,
Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT,
Palumbo A, Samoilova OS, et al VISTA Trial Investigators:
Bortezomib plus melphalan and prednisone for initial treatment of
multiple myeloma. N Engl J Med. 359:906–917. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Kumar S and Rajkumar SV: Many facets of
bortezomib resistance/susceptibility. Blood. 112:2177–2178. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Kuehl WM and Bergsagel PL: Multiple
myeloma: Evolving genetic events and host interactions. Nat Rev
Cancer. 2:175–187. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
48
|
Morgan GJ, Walker BA and Davies FE: The
genetic architecture of multiple myeloma. Nat Rev Cancer.
12:335–348. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Palumbo A and Anderson K: Multiple
myeloma. N Engl J Med. 364:1046–1060. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Rajkumar SV and Buadi F: Multiple myeloma:
New staging systems for diagnosis, prognosis and response
evaluation. Best Pract Res Clin Haematol. 20:665–680. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Kyle RA and Rajkumar SV: Treatment of
multiple myeloma: A comprehensive review. Clin Lymphoma Myeloma.
9:278–288. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Matsui W, Wang Q, Barber JP, Brennan S,
Smith BD, Borrello I, McNiece I, Lin L, Ambinder RF, Peacock C, et
al: Clonogenic multiple myeloma progenitors, stem cell properties,
and drug resistance. Cancer Res. 68:190–197. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Matsui W, Huff CA, Wang Q, Malehorn MT,
Barber J, Tanhehco Y, Smith BD, Civin CI and Jones RJ:
Characterization of clonogenic multiple myeloma cells. Blood.
103:2332–2336. 2004. View Article : Google Scholar
|
